1 Dengue in western Uganda: A prospective cohort of children presenting with 2 undifferentiated febrile illness

3 4

Ross M. Boyce_{1,2*}, Matthew Collins₃, Rabbison Muhindo₂, Regina Nakakande₂, Emily J.
 Ciccone₁, Samantha Grounds₁, Daniel Espinoza₃, Yerun Zhu₃ Michael Matte₂, Moses
 Ntaro₂, Dan Nyehangane_{2.5}Jonathan J. Juliano, 1 and Edgar M. Mulogo₂

- 1Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill,
 9 North Carolina, 27599, USA
- 10
- ²Department of Community Health, Faculty of Medicine, Mbarara University of Science &
 Technology, Mbarara, Uganda
- 14 3Division of Infectious Diseases, Emory University, Atlanta, Georgia, 30322, USA
- 15
- 4College of Arts and Sciences, University of North Carolina at Chapel Hill, Chapel Hill,
 North Carolina, 27599, USA
- 18
- 19 5Epicentre Mbarara Research Centre, Mbarara, Uganda
- 20
- 21 *Corresponding author:22
- 23 Ross M. Boyce MD, MSc
- 24 Division of Infectious Diseases
- 25 University of North Carolina at Chapel Hill
- 26 130 Mason Farm Road
- 27 Chapel Hill, NC USA 27599
- 28 Phone: 919.966.2537
- 29 roboyce@med.unc.edu
- 30

- 31 Keywords: Dengue, fever, arbovirus, epidemiology, Uganda32
- 33 **Running Title:** Dengue in Western Uganda
- 35 Word Count: Abstract 197 | Text 3,087

36 ABSTRACT

Background: The spatial distribution and burden of dengue in sub-Saharan Africa
remains highly uncertain, despite high levels of ecological suitability. The goal of this
study was to describe the epidemiology of dengue among a cohort of febrile children
presenting to outpatient facilities located in areas of western Uganda with differing levels
of urbanicity and malaria transmission intensity.

43 **Methods**: Eligible children were first screened for malaria using rapid diagnostic tests.

44 Children with a negative malaria result were tested for dengue using a combination

45 NS1/IgM/IgG rapid test (SD Bioline Dengue Duo). Confirmatory testing by RT-PCR was

46 performed in a subset of participants. Antigen-capture ELISA was performed to estimate

47 seroprevalence.

48

49 **Results**: Only 6 of 1,416 (0.42%) children had a positive dengue rapid test, while none

50 of the RT-PCR results were positive. ELISA testing demonstrated reactive IgG

51 antibodies in 28 (2.2%) participants with the highest prevalence seen at the urban site in

52 Mbarara (19 of 392, 4.9%, p<0.001).

53

54 **Conclusions**: Overall, these findings suggest that dengue, while present, is an

55 uncommon cause of non-malarial, pediatric febrile illness in western Uganda. Further

56 investigation into the eocological factors that sustain low-level transmission in urban

57 settings are urgently needed to reduce the risk of epidemics.

58 Background

59	Dengue is a mosquito-borne viral disease that is estimated to cause upwards of 400
60	million infections each year [1, 2]. While more than half of the world's population is
61	thought to be at risk, the global distribution and burden of dengue remains highly
62	uncertain [3]. Nowhere is this epidemiological uncertainty more pronounced than in
63	Africa, where the requisite laboratory infrastructure to distinguish dengue from other
64	causes of febrile illness is not routinely available [4]. Despite limited data, there is
65	reasonable consensus for the existence of endemic dengue transmission in many
66	countries, with modeling frameworks suggesting that Africa's disease burden may be
67	similar to that of other high transmission areas, such as the Americas [1].
68	
69	The indirect evidence supporting endemic dengue transmission in Uganda is relatively
70	strong. There are favorable precipitation and temperature conditions, the Aedes aegypti
71	mosquito - the primary vector of dengue, along with yellow fever and Rift Valley fever -
72	is ubiquitous in Uganda. Dengue outbreaks and transmission have been documented in
73	neighboring countries, and cases have been reported among travelers returning from
74	Uganda [1, 5, 6]. Other factors favoring the likelihood of dengue transmission in Uganda
75	include an increasingly globalized economy and rapid urbanization [7, 8].
76	
77	While the majority of dengue infections result in either asymptomatic or mild, self-limited
78	clinical disease, the potential health system and economic impact of dengue
79	transmission in a malaria-endemic country like Uganda is significant but also not well
80	understood. Given the non-specific symptoms and lack of available diagnostic tools,
81	dengue infections may frequently be misdiagnosed and empirically treated as malaria
82	[6]. This likely contributes to (i) over-estimation of malaria transmission, (ii) over-use of
83	artemisinin combination therapies (ACT), perhaps accelerating to the development of

resistance, and (iii) inadequate resourcing of dengue surveillance and control measures,
which generally do not overlap with malaria control strategies such as insecticide-treated
nets (ITN) [9].

87

88 Defining the burden of dengue in countries like Uganda is critically important, especially

as new tools such as vaccines become more widely available [10, 11]. Therefore, the

90 overarching aim of this study was to describe the epidemiology of dengue among a

91 cohort of children presenting to outpatient public health facilities in western Uganda with

- 92 acute febrile illness.
- 93

94 Methods

95 Study Setting

96 The study was conducted at two sites in the Kasese District and one site in the Mbarara

97 District of Southwest Uganda (Figure 1). These facilities were purposefully selected to

98 examine dengue as a potential cause of non-malarial febrile illness across different

99 ecological settings and in areas of varying malaria transmission intensity (**Table 1**).

100 There are no government-provided diagnostic tools or standardized treatment protocols

101 for dengue fever at public health facilities in Uganda [12].

102

103 Study Design

104 The study was a prospective, observational cohort design, enrolling malaria-negative,

105 febrile children from November 2017 to June 2018. Children (age <18 years) presenting

106 to one of three outpatient clinics with documented fever (axillary temperature ≥38₀

107 celsius [C]) or a reported history of fever within the last 7 days were eligible for inclusion.

108 Children presenting without a parent or guardian to provide consent were excluded. After

109 consent was provided, study personnel recorded demographic information, vital signs,

110 and administered a brief health questionnaire.

111

112	Laboratory staff performed a malaria rapid diagnostic test (mRDT) (SD Bioline Malaria
113	Ag P.f, Standard Diagnostics, Republic of Korea) and collected dried blood spots (DBS)
114	on filter paper (Whatman, Chicago, IL). DBS sampling was chosen as a pragmatic but
115	effective option for sampling children across the different field conditions at our study
116	sites [13]. The reliability of measuring antibodies eluted from DBS has been validated
117	several times, [14, 15] and we and others have used DBS-based serology to study the
118	epidemiology of arboviruses in both standard ELISA as well as multiplex platforms [16-
119	18]. Children with a positive mRDT result were excluded from further participation.
120	Children with a negative mRDT result subsequently underwent testing with a dengue
121	rapid diagnostic test (dRDT) (SD Bioline Dengue Duo, Standard Diagnostics Korea).
122	Participants at the Mbarara Regional Referral Hospital outpatient clinic, where a reliable
123	cold chain was available, had 5 mL of venous rather than capillary blood drawn into
124	serum serparator tubes for further testing in addition to the dRDT.
125	
126	Results of the dRDT were provided to the responsible clinician for the purposes of
127	counseling and case management. Treatment and disposition (i.e. admission versus
128	discharge) plans, as determined by the clinician, were recorded. DBS were stored at
129	room temperature under desiccation and serum samples were stored at -20 $_{\circ}$ C until
130	analysis.
101	

131

132 Laboratory Methods

All RDTs for the study were obtained directly from the manufacturer, stored in the
original packaging at room temperature, and used in accordance with the manufacturer's
instructions prior to the expiration date. Further description of specific procedures is

136 provided below.

- 138 Elution of dried blood spots for serologic analysis
- 139 Plasma proteins were eluted from DBS as previously described [16-18]. One 6-mm hole 140 punch of each DBS was placed in a 1.5 mL Eppendorf tube with 300 μ L of phosphate-141 buffered saline, and rotated for 2 hour at 37°C. This yielded an eluate that is equivalent 142 to a 1:40 plasma dilution. Eppendorf tubes were centrifuged then eluate transferred to a 143 new tube. Eluate was heat inactivated for 30 minutes in a 56°C water bath. The samples 144 were centrifuged again to pellet proteinaceous debris and the supernatant was 145 transferred to a new tube and stored at 4°C for up to 1 week or at -20°C until use. 146 Antigen capture IgG ELISA 147 148 Binding IgG to DENV or ZIKV was measured by antigen capture ELISA as previously 149 described [19]. Briefly, DENV antigen (an equal volume mixture of supernatant from 150 each of the four DENV serotypes cultured in C6/36 cells) was captured by the anti-E 151 protein mouse mAb 4G2 [20]. Plates were blocked with 3% nonfat dry milk, and 152 incubated with DBS eluate at 37°C for 1 hour, and binding was detected with an alkaline 153 phosphatase-conjugated goat anti-human IgG secondary Ab and p-nitrophenyl 154 phosphate substrate. Absorbance at 405 nm (optical density, OD) was measured by 155 spectrophotometry on a plate reader. ELISA data are reported as OD values that are the 156 average of technical replicates. The average OD for technical replicates using DBS 157 eluate obtained from flavivirus-naïve individuals (NHS) served as the negative control in 158 ELISA assays. The cut off for positivity was calculated for each plate as the average OD 159 of NHS = standard deviations + 0.1 [16-18]. 160
- 161 IgM ELISA

Testing for anti-DENV IgM was only performed on participant samples with either a
positive dRDT or IgG ELISA per CDC MAC ELISA protocol after titrating individual
reagents per instructions [21]. DBS eluate was tested at 1:40 dilution. DENV1-4 antigen
was the same as for IgG ELISA above. Plates were washed 3 times between each step.
The Enhanced K-Blue TMB substrate reaction was stopped after 30 minutes by addition
of 50 μL 1N HCl. Optical density (OD) of each well was determined within 5 minutes at
450nm.

169

170 Neutralization Assays

171 Neutralization titers were determined by 96-well microFRNT [22, 23]. Due to limited 172 sample availability from DBS, an abbreviated neutralization assay format was used 173 (eFRNT). DBS eluates were run in singleton over four 4-fold dilutions. Serial dilutions of 174 DBS eluate were mixed with approximately 75-100 focus-forming units of virus in DMEM 175 with 2% FBS. The virus-antibody mixtures were incubated for 1 hour at 37°C and then 176 transferred to a monolayer of Vero cells for infection for 2 hours at 37°C. OptiMEM 177 overlay media supplemented with 2% FBS and 5g (1%) Carboxymethylcellulose was 178 then added, and cultures were incubated for 48 hours (DENV2 and DENV4) or 52 hours 179 (DENV1, DENV3). Cells were fixed with 100 µL of 1:1 methanol:acetone for 30 minutes. 180 100 µL of permeabilization buffer was added for 10 minutes followed by 100 µL of 181 blocking buffer (3% normal goat plasma in permeabilization buffer) and left overnight at 182 4° C. 50 μ L of 4G2 at 12.5 ng/ μ L were added to the plates and incubated for 1 hour at 183 37°C. Cells were washed with a microplate washer followed by the addition of 50 µl of 184 1:3000 horseradish peroxidase-conjugated goat anti-mouse secondary antibody for 1 185 hour at 37°C. Foci were visualized with 100 µL of True Blue and counted with a user-186 supervised automated counting program on 2x-magnified images of micro-wells

187 obtained on a CTL ELISPOT reader. NHS controls were included on every plate to

define 100% infection. The eFRNT value is a discrete number corresponding to the

189 dilution factor at which 50% maximum FFU are observed or the average of the two

- 190 dilution factors between which 50% FFU is crossed.
- 191
- 192 Real-time Polymerase Chain Reaction
- 193 Whole blood was drawn into serum serparator tubes and centrifuged. Viral RNA was
- 194 extracted from 140 µL of serum using the QIAamp extraction kit (QIAGEN Hilden,
- 195 Germany) and eluted in 60 µL. Real time PCR was performed on the Rotor-Gene Q
- 196 (QIAGEN Hilden, Germany) platform using the RealStar ® kits for Dengue, V2.0,
- 197 Chikungunya, V2.0 and Zika V.1.0 (Altona Diganostics, Hamburg, Germany) in
- 198 accordance with manufacturer's instructions.
- 199

200 Statistical analysis

- 201 Data was collected in a REDCap database and analyzed with Stata 15.1 (College
- 202 Station, TX) [24]. We summarized participant characteristics and compared them
- 203 between those with positive and negative mRDT resuts using Student's t-test (normally
- 204 distributed data) or Wilcoxon rank-sum test (nonparametric data) for continuous
- 205 variables and Pearson χ2 test for categorical variables. In a post-hoc analysis, we
- 206 performed multivariable regression analyses to explore the demographic, geographic,
- and clinical parameters associated with the primary outcome of interest: a positive
- 208 dengue IgG. All variables that were significant in univariate models with a pre-specified
- 209 *p*-value of <0.25 were included in the subsequent multivariate analysis [25]. A resulting
- 210 *p*-value of <0.05 was considered statistically significant in the final models.
- 211

212 Results

213	A total of 1,702 children met the eligibility criteria and were screened for malaria with a
214	mRDT. Complete laboratory results were available for 1,693 (99.5%) particpants, who
215	were subsequently included in the analysis. Characteristics of the cohort are
216	summarized in Table 2 . The median age was 5 years (IQR $2 - 10$), although children at
217	Bugoye were significantly older (10 years, IQR 5 – 14, p<0.0001), likely attributable to an
218	existing village-based, community health worker led fever management intervention
219	targeting children less than five years of age and reducing the number of these patients
220	that presented to our study site [26].
221	
222	Overall, 369 children (21.8%) had a positive mRDT result. The lowest rate was observed
223	at MRRH (17 of 455, 3.7%, 95% CI 2.3 – 5.9), whereas much higher rates were seen in
224	Kasese (138 of 606, 22.8%, 95% CI 19.6 – 26.3) and Bugoye (214 of 632, 33.9%, 95%
225	CI 30.3 – 37.7). Self-reported ITN use was associated with a protective effect against
226	malaria (IRR 0.70, 95% CI 0.54 – 0.90, p=0.006), but when excluding the low-
227	transmission site, the effect was no longer significant (IRR 0.85, 95% CI 0.65 – 1.11,
228	p=0.25).
229	

229

230 There was overlap in self-reported symptoms between children with positive and

negative mRDT results (**Table 2**). Among all participants, cough (69.1%), headache

232 (63.6%), and rhinorrhea (53.0%) were the most frequently reported symptoms. A total of

431 (25.4%) participants reported all three of these symptoms, 364 (84.5%) of whom

had a negative mRDT result. Participants with a negative mRDT were also more likely to

have sought care and received treatment for malaria within the past 14 days. In contrast,

arthralgia and myalgia were more frequently reported in the mRDT positive group.

237

Of the 1,324 participants with a negative mRDT test result, 1,285 (97.1%) had an
evaluable dRDT result, of which 5 (0.39%) had a positive result, defined as a visible
NS1, IgM, or IgG band. Individual tests results include one child with positive IgM bands,
three with positive IgG bands, and one with positive IgM and IgG bands. There were
three positive dRDT results in Bugoye, two in Mbarara, and and one in Kasese (Figure
All samples from MRRH tested by RT-PCR were negative for DENV, CHIKV, and
ZIKV.

245

246 Serological testing of 1,247 DBS samples from participants with a negative mRDT test

result identified reactive IgG antibodies in 28 (2.3%) participants. There was a significant

difference in seroprevalence between Mbarara (19 of 392, 4.9%), which is a more urban

249 center, and the rural sites (Kasese 2 of 453, 0.4%; Bugoye 7 of 414, 1.7%; p<0.001).

250 The Mbarara study site was the only significant predictor of a dengue infection in the

251 multivariable analysis when using Kasese as the reference, although there was a

statistical trend towards males being at higher risk of infection (p=0.10) (**Table 3**).

253 Samples that were positive by RDT or IgG ELISA were also tested by eFRNT and DENV

254 IgM-ELISA, but none were positive for IgM antibodies.

255

Of the 28 participants with a reactive IgG antibodies by ELISA, only 1 (3.6%) had a

257 positive IgG band on the dRDT. This occurred in the one patient with both IgM and IgG

bands positive on the dRDT. Overall, the correlation in IgG results between the dRDT

259 and ELISA was poor ($\kappa = 0.06, 95\%$ Cl 0 – 0.40).

260

Among those with a negative mRDT result, 1,297 of 1,324 (98.0%) received treatment

262 with an antibiotic, including five who also received treatment with

artemether/lumefantrine (AL). An additional 17 (1.3%) received treatment with AL (and

no antibiotic) despite negative mRDT test results. The vast majority of children (1,279 of
1,316, 97.2%) were discharged from the outpatient clinics, while 35 (2.7%) were
admitted. There were no significant differences in admission rates by sex, age category,

- or clinical site.
- 268

269 **Discussion**

270 Despite favorable climate and ecology, our findings suggest that dengue is an

271 uncommon cause of non-malarial, pediatric febrile illness in western Uganda. Our results

are consistent with those obtained from a laboratory-based surveillance system of

273 inpatient pediatric admissions across six sentinel sites in Uganda, which reported recent

arboviral infection in only 18 of 622 (2.9%) samples tested [27], as well as multi-site

275 seroprevalence study of healthy adult blood donors, which identified dengue antibodies

in 72 of 1,744 (4.1%) of donors [28]. However, these data exclude neither the possibility

of sporadic dengue outbreaks in the past or future nor the possibility that dengue or

278 other Aedes-borne viruses could establish endemicity in this region given the favorable

279 ecological conditions. Our time-limited and geographically-restricted study design,

280 however, does provide a robust snapshot of current arbovirus transmission. While

seroprevalence studies that include older subjects may increase the sensivtivity for

282 detecting historic dengue transmission, our findings do provide strong evidence for the

283 presence of low-level transmission, particularly at the more urban site in Mbarara. In

areas of higher transmission, dengue seroprevalence is typically 20% or greater in

285 young children [29-31]. The few cases detected here, along with the large susceptible

286 population make dengue introduction a major concern, and surveillance together with

further investigation of the demographic, spatial, and entomologic factors that could

support epidemic and endemic dengue infection in urban East Africa should be a high

289 priority.

287

290

291	Given the low number of positive cases, a rigorous assessment of the performance of
292	the dengue rapid diagnostic tests was not possible. The relatively poor correlation in IgG
293	results between the dRDT and the ELISA is consistent with a study of febrile outpatients
294	conducted in the Democratic Republic of Congo, which showed 2.5% IgG positivity by
295	dRDT and 34.0% positivity by ELISA with an estimated sensitivity of 7.6% [32]. It is
296	crucial to note that dRDT are designed for use in the setting of acute infection and not
297	for seroprevalence studies. The main advantage of including IgG testing in this context is
298	in secondary infection, when IgG may rise quickly and dramatically, suppressing the IgM
299	response and limiting unbound dengue antigen present in serum [33]. In primary
300	infection, patients would typically present before an IgG response has developed. A
301	recent systematic review evaluated the potential of dRDT to function as a measure of
302	seroprevalence but found performance to be suboptimal, with sensitivity ranging from
303	30-60% [34].

304

305 Our results do highlight the urgent need for better diagnostics and management 306 algorithms for children with acute febrile illness. Malaria was identified as the cause of 307 fever in only 22% of participants, and among participants with a negative malaria test, 308 nearly 80% reported cough or rhinorrhea with more than half (51.1%) reporting both 309 symptoms. While not confirmed by microbiologic or molecular methods, many of these 310 children likely had viral infections that would be self-limited and not require antibiotic 311 treatment [35]. Yet more than 97% of children with a negative malaria test result across 312 all three sites received a course of antibiotic treatment. Given the growing global threat 313 of antimicrobial resistance, driven in part by antimicrobial overuse, this patient population 314 represents an important target for antibiotic stewardship interventions.

315

316 To our knowledge, our study is one of the first to examine the burden of dengue among 317 children presenting to outpatient clinics in western Uganda with undifferentiated febrile 318 illness. Strengths of our approach include the diverse geography of the clinical sites, 319 large sample size, and different diagnostic testing strategies (i.e. dRDT, ELISA, PCR). 320 The study also has a number of limitations. First, we excluded children with a positive m 321 RDT from further consideration. While dengue-malaria coninfections have been reported 322 in other settings [6], this was expected to be a relatively infrequent occurrence. To 323 explore this possibility, however, we tested 131 mRDT positive children at the Kasese 324 site, only one (0.77%) of who had a positive IgM band on the dRDT; a prevalence similar 325 to children with a negative mRDT (p=0.53). Second, our facility-based and temporally-326 limited enrollment strategy may have missed focal outbreaks of dengue in the 327 community. Dengue is well-known to emerge rapidly in non-immune populations then 328 quickly disappear. Studies from neighboring countries and other sureveillance methods 329 do, however, support he validity of our findings. Third, IgG ELISA may overestimate 330 dengue prevalence as this assay may also detect cross-reactive antibodies elicited by 331 infection by related flaviviruses, though neutralization testing also supported prior 332 infection by dengue for some subjects in this population [36, 37]. Lastly, we did not have 333 the means to screen all specimens for anti-dengue IgM, which precluded a direct 334 comparison of serologic IgM testing to the dRDT result.

335

336 Conclusions

337 Dengue does not account for a large proportion of non-malarial, acute febrile illness
 338 presentations in western Uganda. However, the presence of the vector and the

339 pathogen, along with a large susceptible population make sporadic outbreaks a major

- 340 concern. Further investigation into the eocological factors that sustain low-level
- 341 transmission in urban centers such as our Mbarara site, are urgently needed.

342 Abbreviatiions

343	ACT	Artemisinin combination therapies
344	AL	Artemether/lumefantrine
345	Co	Degress celsius
346	CHIKV	Cikunguunya Virus
347	DBS	Dried Blood Spot
348	DENV	Dengue Virus
349	dRDT	Dengue rapid diagnostic test
350	ELISA	Enzyme Linked immunosorbent Assay
351	ITN	Insecticide-treated nets
352	mRDT	Malaria rapid diagnostic test
353	MRRH	Mbarara Regional Referral Hospital
354	NS1	Non-structural protein 1
355	OD	Optical Density
356	RNA	Ribonucleic acid
357	RT-PCR	Reverse-Transcriptase Polymerase Chain Reaction
358	ZIKV	Zika Virus

359 **Declarations**

- 360 Ethics Approval and Consent to Participate
- 361 Ethical approval of the study was provided by the institutional review boards of the
- 362 University of North Carolina at Chapel Hill, the Mbarara University of Science and
- 363 Technology, and the Uganda National Council for Science and Technology. Written
- 364 informed consent for participation in the study was obtained from all adult participants or
- 365 from their parent or guardian when participants were children (under 18 years old).
- 366

367 Competing Interests

368 All authors have completed the ICMJE uniform disclosure form and declare: no financial

369 relationships with any organisations that might have an interest in the submitted work in

370 the previous three years; no other relationships or activities that could appear to have

- influenced the submitted work.
- 372
- 373 Consent for Publication
- Not applicable.
- 375

376 Funding

The study was supported by Takeda Vaccines. Standard Diagnostics provided the rapid diagnostic tests for the study at no cost. RMB is supported by the National Institutes of Health (K23AI141764). JJJ received support from National Institute of Health (K24AI13499). EJC is supported by the National Institutes of Health (5T32HL007106-43). Neither Takeda nor Standard Diagnostics nor had any role in the design or conduct of the study or preparation of the manuscript.

383

384 Author Contributions

- 385 Study conception and design: RMB, MHC, EM. Funding: RMB. Study implementation:
- 386 RMB, RM, RK, EC MM, MN, DN, EM. Laboratory testing: RK, DN, SG, DE, YZ, MHC. First
- 387 draft of manuscript: RMB, SG, EC, MHC, DN. Revisions: All.
- 388
- 389 Availability of Data and Materials
- 390 Deidentified individual data that supports the results will be shared beginning 9 to 36
- 391 months following publication provided the investigator who proposes to use the data has
- 392 approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC),
- 393 or Research Ethics Board (REB), as applicable, and executes a data use/sharing
 394 agreement with UNC.
- 395
- 396 Acknowledgements
- 397 We wish to thank the clinical staff and patients of the Bugoye Health Centre, Kasese
- 398 Health Centre, and Mbarara Regional Referral Hospital Outpatient Department for their
- 399 participation and support. We also thank Corinna Keeler for the cartography support.

400		REFERENCES
401 402 403 404	1.	Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O <i>et al</i> : The global distribution and burden of dengue . <i>Nature</i> 2013, 496 (7446):504-507.
405 406	2.	Simmons CP, Farrar JJ, Nguyen v V, Wills B: Dengue . <i>The New England journal of medicine</i> 2012, 366 (15):1423-1432.
407 408 409 410	3.	Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI: Refining the global spatial limits of dengue virus transmission by evidence-based consensus . <i>PLoS neglected tropical diseases</i> 2012, 6 (8):e1760.
411 412 413	4.	WHO: WHO report on global surveillance of epidemic-prone infectious diseases: dengue and dengue haemorrhagic fever. In. Geneva: World Health Organization; 2014.
414 415	5.	Amarasinghe A, Kuritsk JN, Letson GW, Margolis HS: Dengue virus infection in Africa . <i>Emerging infectious diseases</i> 2011, 17 (8):1349-1354.
416 417 418 419	6.	Chipwaza B, Mugasa JP, Selemani M, Amuri M, Mosha F, Ngatunga SD, Gwakisa PS: Dengue and Chikungunya fever among viral diseases in outpatient febrile children in Kilosa district hospital, Tanzania . <i>PLoS neglected tropical diseases</i> 2014, 8 (11):e3335.
420 421 422	7.	Jaenisch T, Junghanss T, Wills B, Brady OJ, Eckerle I, Farlow A, Hay SI, McCall PJ, Messina JP, Ofula V <i>et al</i> : Dengue expansion in Africa-not recognized or not happening? <i>Emerging infectious diseases</i> 2014, 20 (10).
423 424	8.	Statistics UBo: National Population and Housing Census 2014 . In. Kampala: Republic of Uganda; 2014.
425 426	9.	Anders KL, Hay SI: Lessons from malaria control to help meet the rising challenge of dengue. The Lancet Infectious diseases 2012, 12(12):977-984.
427 428 429 430	10.	Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, Sirivichayakul C, Watanaveeradej V, Rivera L, Espinoza F <i>et al</i> : Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents . <i>The New England</i> <i>journal of medicine</i> 2019, 381 (21):2009-2019.
431 432 433 434	11.	Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramirez JO, Carrasquilla G <i>et al</i> : Efficacy of a tetravalent dengue vaccine in children in Latin America . <i>The New England journal of medicine</i> 2015, 372 (2):113-123.
435 436	12.	Uganda Ministry of Health: National Guidelines for the Management of Common Conditions. In. Kampala, Uganda; 2016.
437 438 439	13.	Lim MD: Dried Blood Spots for Global Health Diagnostics and Surveillance: Opportunities and Challenges. The American journal of tropical medicine and hygiene 2018, 99(2):256-265.

- 440 14. Andersen NJ, Mondal TK, Preissler MT, Freed BM, Stockinger S, Bell E, Druschel C,
 441 Louis GM, Lawrence DA: Detection of immunoglobulin isotypes from dried blood
 442 spots. *J Immunol Methods* 2014, 404:24-32.
- Behets F, Kashamuka M, Pappaioanou M, Green TA, Ryder RW, Batter V, George JR,
 Hannon WH, Quinn TC: Stability of human immunodeficiency virus type 1
 antibodies in whole blood dried on filter paper and stored under various tropical
 conditions in Kinshasa, Zaire. J Clin Microbiol 1992, 30(5):1179-1182.
- Corbett KS, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM:
 Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. *J Infect Dis* 2015, 211(4):590-599.
- Tissera H, Amarasinghe A, De Silva AD, Kariyawasam P, Corbett KS, Katzelnick L, Tam C, Letson GW, Margolis HS, de Silva AM: Burden of dengue infection and disease in a pediatric cohort in urban Sri Lanka. The American journal of tropical medicine and hygiene 2014, 91(1):132-137.
- Willcox AC, Collins MH, Jadi R, Keeler C, Parr JB, Mumba D, Kashamuka M, Tshefu A, de Silva AM, Meshnick SR: Seroepidemiology of Dengue, Zika, and Yellow Fever
 Viruses among Children in the Democratic Republic of the Congo. The American journal of tropical medicine and hygiene 2018, 99(3):756-763.
- de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ,
 Diamond MS, Baric RS, Crowe JE, Jr. *et al*: Identification of human neutralizing
 antibodies that bind to complex epitopes on dengue virions. *Proc Natl Acad Sci U S*A 2012, 109(19):7439-7444.
- 463 20. Henchal EA, Gentry MK, McCown JM, Brandt WE: Dengue virus-specific and
 464 flavivirus group determinants identified with monoclonal antibodies by indirect
 465 immunofluorescence. The American journal of tropical medicine and hygiene 1982,
 466 31(4):830-836.
- 467 21. Martin DA, Muth DA, Brown T, Johnson AJ, Karabatsos N, Roehrig JT: Standardization
 468 of immunoglobulin M capture enzyme-linked immunosorbent assays for routine
 469 diagnosis of arboviral infections. *J Clin Microbiol* 2000, **38**(5):1823-1826.
- Collins MH, McGowan E, Jadi R, Young E, Lopez CA, Baric RS, Lazear HM, de Silva
 AM: Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from
 Dengue Virus Infection. *Emerging infectious diseases* 2017, 23(5):773-781.
- 473 23. Swanstrom JA, Plante JA, Plante KS, Young EF, McGowan E, Gallichotte EN, Widman DG, Heise MT, de Silva AM, Baric RS: Dengue Virus Envelope Dimer Epitope
 475 Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika
 476 Virus. *mBio* 2016, 7(4).
- 47724.Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG: Research electronic478data capture (REDCap)--a metadata-driven methodology and workflow process for479providing translational research informatics support. J Biomed Inform 2009,48042(2):377-381.
- 481 25. Hosmer D, Lemeshow, S: Applied Logistic Regression. New York: Wiley; 2000.

- 482 26. English L, Miller JS, Mbusa R, Matte M, Kenney J, Bwambale S, Ntaro M, Patel P,
 483 Mulogo E, Stone GS: Monitoring iCCM referral systems: Bugoye Integrated
 484 Community Case Management Initiative (BIMI) in Uganda. Malaria journal 2016,
 485 15:247.
- Lamorde M, Mpimbaza A, Walwema R, Kamya M, Kapisi J, Kajumbula H, Sserwanga A, Namuganga JF, Kusemererwa A, Tasimwa H *et al*: A Cross-Cutting Approach to
 Surveillance and Laboratory Capacity as a Platform to Improve Health Security in
 Uganda. *Health Secur* 2018, 16(S1):S76-S86.
- 490 28. Clements TL, Rossi CA, Irish AK, Kibuuka H, Eller LA, Robb ML, Kataaha P, Michael NL,
 491 Hensley LE, Schoepp RJ: Chikungunya and O'nyong-nyong Viruses in Uganda:
 492 Implications for Diagnostics. Open Forum Infect Dis 2019, 6(3):ofz001.
- 493 29. L'Azou M, Assoukpa J, Fanouillere K, Plennevaux E, Bonaparte M, Bouckenooghe A,
 494 Frago C, Noriega F, Zambrano B, Ochiai RL *et al*: Dengue seroprevalence: data from
 495 the clinical development of a tetravalent dengue vaccine in 14 countries (2005496 2014). Trans R Soc Trop Med Hyg 2018, 112(4):158-168.
- 49730.Reller ME, de Silva AM, Miles JJ, Jadi RS, Broadwater A, Walker K, Woods C, Mayorga498O, Matute A: Unsuspected Dengue as a Cause of Acute Febrile Illness in Children499and Adults in Western Nicaragua. PLoS neglected tropical diseases 2016,50010(10):e0005026.
- 50131.Rojas DP, Barrera-Fuentes GA, Pavia-Ruz N, Salgado-Rodriguez M, Che-Mendoza A,502Manrique-Saide P, Vazquez-Prokopec GM, Halloran ME, Longini IM, Gomez-Dantes H:503Epidemiology of dengue and other arboviruses in a cohort of school children and504their families in Yucatan, Mexico: Baseline and first year follow-up. PLoS neglected505tropical diseases 2018, 12(11):e0006847.
- Solo 32. Proesmans S, Katshongo F, Milambu J, Fungula B, Muhindo Mavoko H, Ahuka-Mundeke S, Inocencio da Luz R, Van Esbroeck M, Arien KK, Cnops L *et al*: Dengue and chikungunya among outpatients with acute undifferentiated fever in Kinshasa, Democratic Republic of Congo: A cross-sectional study. *PLoS neglected tropical diseases* 2019, 13(9):e0007047.
- 33. Peeling RW, Artsob H, Pelegrino JL, Buchy P, Cardosa MJ, Devi S, Enria DA, Farrar J,
 512 Gubler DJ, Guzman MG *et al*: Evaluation of diagnostic tests: dengue. Nat Rev
 513 Microbiol 2010, 8(12 Suppl):S30-38.
- 51434.Luo R, Fongwen N, Kelly-Cirino C, Harris E, Wilder-Smith A, Peeling RW: Rapid515diagnostic tests for determining dengue serostatus: a systematic review and key516informant interviews. Clin Microbiol Infect 2019, 25(6):659-666.
- 517 35. D'Acremont V, Kilowoko M, Kyungu E, Philipina S, Sangu W, Kahama-Maro J, Lengeler
 518 C, Cherpillod P, Kaiser L, Genton B: Beyond malaria--causes of fever in outpatient
 519 Tanzanian children. *The New England journal of medicine* 2014, 370(9):809-817.
- Allwinn R, Doerr HW, Emmerich P, Schmitz H, Preiser W: Cross-reactivity in flavivirus serology: new implications of an old finding? *Med Microbiol Immunol* 2002, 190(4):199-202.
- 523 37. Speer SD, Pierson TC: VIROLOGY. Diagnostics for Zika virus on the horizon.
 524 Science 2016, 353(6301):750-751.
 525
- 19

Table 1: Description	of clinical sites
----------------------	-------------------

Study Site	Location	District	GPS	Elevation	Setting	Facility Type	Referral Base	Monthly Clinic Visits	Malaria Prevalence*
Bugoye Health Centre III	Bugoye Village	Kasese	0₀ 30' N 30₀ 1' E	1,242m	Rural	Public Health Centre III	50,000	800	17.6%
Kasese Health Centre III	Kasese Town	Kasese	0₀ 17' N 30₀ 7' E	980m	Semi- Urban	Public Health Center III	400,000	1,200	17.6%
Mbarara Regional Referral Hospital	Mbarara Town	Mbarara	0₀ 36' S 30₀ 4' E	1,442m	Urban	Public Teaching Hospital	2.5 million	1,600	5.7%

*Regional estimates from 2014-15 Uganda Malaria Indicator Survey

Characteristic	All	Malaria RDT Positive	Malaria RDT Negative	<i>p</i> -Value
Patients (n, %)	1,693 (100)	369 (21.8)	1,324 (78.2)	-
Age, (median, IQR)	5 (2 – 10)	7 (4 – 11)	4 (2 – 9)	<0.001*
< 5 years	788 (46.5)	122 (33.1)	666 (50.3)	
5 – 12 years	577 (34.1)	155 (42.0)	422 (31.9)	<0.001
≥ 12 years	328 (19.4)	92 (24.9)	236 (17.8)	
Female sex (n, %)	904 (53.4)	200 (54.2)	704 (53.2)	0.73
Recruitment Site (n, %)				
Bugoye	632 (37.3)	214 (58.0)	418 (31.6)	
Kasese	606 (35.8)	138 (37.4)	468 (35.4)	<0.001
Mbarara	455 (26.9)	17 (4.6)	438 (33.1)	
Slept under bednet (n, %)	1,222 (73.0)	244 (67.2)	978 (74.5)	0.005
Excluding Mbarara	858 (70.3)	235 (67.9)	623 (71.3)	0.25
Days since fever onset (median, IQR)*	3 (2 – 3)	3 (2 – 3)	3 (2 – 3)	0.0008*
Reported Symptoms				
Anorexia/Poor ⁻ eeding	234 (13.8)	56 (15.2)	178 (13.4)	0.39
Arthralgia	170 (10.0)	64 (17.3)	106 (8.0)	<0.001
Cough	1,178 (69.1)	208 (56.1)	970 (72.7)	<0.001
Diarrhea	234 (13.8)	34 (9.2)	200 (15.1)	0.004
Headache	1,076 (63.6)	276 (74.8)	800 (60.4)	<0.001
Myalgia	143 (8.5)	59 (16.0)	84 (6.3)	<0.001
Rash	92 (5.4%)	15 (4.1)	77 (5.8)	0.19
Rhinorrhea	897 (53.0)	134 (36.3)	763 (57.6)	<0.001
Seizures	6 (0.4)	1 (0.3)	5 (0.4)	0.76
Vomiting	248 (14.7)	46 (12.5)	202 (15.3)	0.18
Abnormal Vital Signs (n, %)				
Febrile (T ≥38₀ C)	281 (16.6)	75 (20.3)	206 (15.6)	0.03
Hypoxia (SpO2 <90%)	93 (5.5)	12 (3.3)	81 (6.2)	0.03
Previously seen at nealth center for same condition?	252 (15.0)	30 (8.2)	222 (16.8)	<0.001
Taken antimalarials in he last two weeks?	175 (10.4)	26 (7.1)	149 (11.3)	0.02

Table 2: Demographic and clinical characteristics of the study cohort

Abbreviations: RDT = rapid diagnostic test; IQR = interquartile range; C_0 = degrees celsisus; SpO2 = oxygen saturation as measured by pulse oximeter. *Determined using Wilcoxon Rank Sum

Variable		Unadjusted		Adjusted*			
	OR	95% CI	<i>p</i> -value	aOR	95% CI	<i>p</i> -value	
Male sex	2.08	0.95 - 4.54	0.07	1.93	0.88 – 4.25	0.10	
Age category							
< 5 years		REF					
5 – 12 years	1.42	0.62 - 3.25	0.41				
\geq 12 years	1.10	0.39 – 3.16	0.86				
Study site							
Kasese		REF			REF		
Bugoye	3.88	0.80 – 18.8	0.09	4.08	0.84 – 19.8	0.08	
Mbarara	11.5	2.66 - 49.6	0.001	11.2	2.59 – 48.5	0.001	
Bednet use	1.61	0.61 – 4.27	0.34				

Table 3: Regression modeling of variables associated with presence of dengue IgG

* Variables that were significant in univariate models with a pre-specified P-value of <0.25 were included in the subsequent multivariate analysis

FIGURE LEGENDS

Figure 1: Map showing location of study sites and population density of each location.

Figure 2: Summary of study participantion and test results stratified by study site.



